ClinicalTrials.gg
Not yet recruitingNCT07758231TAPUpdated Oct 29, 2026

Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics

A Phase 1 interventional study of Acute Ethanol Dose in GLP-1 and Alcohol, sponsored by University of Wisconsin, Madison. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of Wisconsin, Madison · Phase 1, Interventional, and Basic science

Updated Oct 29, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
21 Years to 55 Years
Sex
All
01

Study summary

This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.

Read the detailed description

Participants will:

  • Arrive to study visit in a fasted state
  • Provide blood, breath, and urine samples prior to intervention
  • Complete baseline cognitive assessments
  • Self-administer the intervention (time 0), followed by breakfast (time 30 minutes)
  • Complete subjective and cognitive assessments throughout treatment visit
  • Provide blood, breath, and urine samples throughout treatment visit
  • Consume lunch 260 minutes after dosing
  • Complete study visit at 360 minutes
  • Complete a final study survey

Primary Objective: Characterize the pharmacokinetics of ethanol in participants receiving maintenance Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) therapy (tirzepatide).

Secondary Objectives:

- Determine the effects of GLP-1 RA therapy on alcohol-induced impairment, as measured by

  • objective performance
  • subjective impairment assessments
  • risk perception

Correlative Objectives

  • Define the exposure-response relationship between biological alcohol concentrations (breath and blood) and functional impairment to determine if Primary Objective
  • Characterize the pharmacokinetics of ethanol in participants receiving maintenance GLP-1 RA therapy (tirzepatide).
02

Conditions studied

  • GLP-1
  • Alcohol
03

In context

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,189 studies on the registry; 181 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 21 years of age, no older than 55 years of age
  • 30-45 kg/m2
  • Taking stable dose of prescribed, branded tirzepatide for at least 28 days
  • Self-reported regular alcohol consumption
  • Good mental health as determined by self-reported responses to the Psychopathology Screener and review by Study Physician as necessary
  • Absence of any major medical, cardiovascular, endocrine, and neurological condition as determined by self-reported responses to the Medical History Screener
  • In possession of a valid drivers' license with at least two years of driving experience
  • English-speaking (able to provide consent and complete questionnaires)
  • Written

Exclusion criteria

Exclusion Criteria:

  • AUDIT score of >8 requires Study Physician review
  • Use of compounded GLP-1 RA
  • History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener, Drug Use Disorders Identification Test, Alcohol Use Disorder Identification Test
  • Pregnancy or lactation (pregnancy test, if needed)
  • Use of medications that may impact cognitive ability or potentiate alcohol (e.g., mood stabilizers, sedatives)
  • Use of medications that are known to significantly delay gastric emptying as determined by Study Physician
  • History of pancreatitis, severe gastroparesis, or personal or family history of medullary thyroid or multiple endocrine neoplasia syndrome type 2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Healthy adults on Tirzepatide

    Participants will complete a screening and enrollment visit, one study visit, and a follow-up correspondence over the course of approximately 4 weeks.

    Drug: Acute Ethanol Dose

Interventions

  • DrugAcute Ethanol Dose

    Time 0, participants will self-administer an oral ethanol beverage (vodka and sugar-free cherry Kool aid) calculated to reach a peak Breath Alcohol Concentration (BrAC) of 0.08 g/dL using the Widmark formula. A total time of 30 minutes will be given for completion of beverage consumption. This will be followed by a breakfast.

    Also known as: vodka

This study also gives Tirzepatide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Maximum Ethanol Concentration (Cmax)

    Cmax will be determined from visual inspection of the concentration-time plots.

    Time frame: prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes

  2. Time to Maximum Ethanol Concentration (Tmax)

    Tmax will be determined from visual inspection of the concentration-time plots.

    Time frame: prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes

  3. Ethanol Elimination Rate: Blood samples

    Data derived from blood samples.

    Time frame: prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes

  4. Ethanol Elimination Rate: Breath tests

    Data derived from breath alcohol test.

    Time frame: prior to dosing (-25 minutes), 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes

  5. Ethanol Elimination Rate: Urine samples

    Data derived from urine samples.

    Time frame: prior to dosing (-25 minutes), 60 minutes, 120 minutes, 180 minutes, 240 minutes, 300 minutes

Secondary outcomes

  1. Biphasic Alcohol Effects Scale (BAES) Score

    The BAES has 2 subscales: Stimulant scored from 0-70 and Sedative scored from 0-70. Higher scores indicate higher stimulant or sedative effects.

    Time frame: 5 minutes, 35 minutes, 65 minutes, 95 minutes, 125 minutes, 185 minutes, 245 minutes, 290 minutes, 340 minutes

  2. Risk Perception and Safety Appraisal (RPSA) Score

    To quantify cognitive and affective dimensions of risk perception, participants will complete the RPSA questionnaire assessing cognitive and affective risk perception, behavioral risk willingness, metacognitive calibration, and consequence awareness. This RPSA has been designed by the study team to provide a low burden (12-item), repeatable measure of cognitive, affective, and behavioral dimensions of risk perception, and direct quantification of willingness to engage in safety sensitive behavior. Scores range from 0-100 where higher scores indicate increased risk perception.

    Time frame: 5 minutes, 35 minutes, 65 minutes, 95 minutes, 125 minutes, 185 minutes, 245 minutes, 290 minutes, 340 minutes

  3. Divided Attention Task (DAT)

    Participants will be asked to complete a computer-based DAT on a laptop in their room. The DAT requires participants to track a moving stimulus on a computer screen while simultaneously monitoring numbers located in the corners of the screen. Participants must respond to target numbers as they appear, and the task quantifies the mean distance of the mouse cursor from the center of the target stimulus.

    Time frame: prior to dosing (-20 minutes), 10 minutes, 100 minutes, 220 minutes

  4. Digital Symbol Substitution Task (DSST)

    Participants will be asked to complete a computer-based DSST on a laptop in their room. The DSST asks participants to recreate patterns of various shapes presented on a computer screen using the keyboard. The total number of correct patterns are recorded within 90 seconds.

    Time frame: prior to dosing (-20 minutes), 10 minutes, 100 minutes, 220 minutes

  5. Paced Serial Addition Task (PSAT)

    Participants will be asked to complete a computer-based PSAT on a laptop in their room. The PSAT has participants view a string of single-digit numbers and calculate the sum of the two most recently presented numbers. The total number of correct trials out of 90 will be recorded.

    Time frame: prior to dosing (-20 minutes), 10 minutes, 100 minutes, 220 minutes

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Data, including transcriptions of audio-recordings of the driving simulator experiments and biological specimens, will be stored for future use. The original digital audio recordings will not be banked for future use, only the transcription documents containing only experiment-relevant words spoken by the participant will be kept. Only members of the study team will have access to the data and specimens. Prior to banking, identifiers (including linking codes) will be removed from the data and biological specimens. Since identifiers will be removed from the data and biological specimens, participants will not be able to withdraw their banked data and specimens from future research use. Data will be released only as anonymized aggregates after careful consideration and approval of one of the study PIs. No genetic testing will take place on any banked biological specimen.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Oct 2026 → Nov 2026, primary completion Mar 2027 → Apr 2027 and completion Mar 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 11, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Apr 2027was Mar 2027
CompletionEst.
Apr 2027was Mar 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Nov 2026
Oct 29, 2026
Primary completion
Mar 2027→Apr 2027
Oct 29, 2026
Study completion
Mar 2027→Apr 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Start date Oct 2026→Nov 2026
    Primary completion Mar 2027→Apr 2027
    Study completion Mar 2027→Apr 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07758231
Responsible party
Sponsor
First posted
Aug 11, 2026
Start date
Nov 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Heather Barkholtz, PhD
Contact
hbarkholtz@wisc.edu
608-890-1967
Michael Chen, MD
Contact
michael.chen@fammed.wisc.edu
Heather Barkholtz, PhD
principal investigator · UW School of Pharmacy
Michael Chen, MD
principal investigator · UW School of Medicine and Public Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion